Read "Her-2 : The Making of Herceptin, a Revolutionary Treatment for Breast Cancer" if you haven't already. It was published in 1998, so is now "old," but it still gives an interesting perspective on breast cancer in particular and the biotech industry in general. (Actually, maybe it's better as an overview of the biotech industry.)
Although Herceptin only helps the 25-30% of breast cancer patients that overexpress Her-2, they tend to be the ones whose survival is shortest.
Market Data 
Markets 
AI
